Biliary Tract Cancer (BTC) Clinical Trials

7 recruiting

Biliary Tract Cancer (BTC) Trials at a Glance

7 actively recruiting trials for biliary tract cancer (btc) are listed on ClinicalTrialsFinder across 6 cities in 3 countries. The largest study group is Phase 1 with 3 trials, with the heaviest enrollment activity in Duarte, New York, and Boston. Lead sponsors running biliary tract cancer (btc) studies include J-Pharma Co., Ltd., Peking Union Medical College Hospital, and I-Mab Biopharma US Limited.

Browse biliary tract cancer (btc) trials by phase

Treatments under study

About Biliary Tract Cancer (BTC) Clinical Trials

Looking for clinical trials for Biliary Tract Cancer (BTC)? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Biliary Tract Cancer (BTC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Biliary Tract Cancer (BTC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting

In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of New Technologies to Tackle Hepato-Pancreato-Biliary Cancers

Pancreatic CancerCholangiocarcinomaPancreatic Cyst+4 more
University of Nottingham160 enrolled1 locationNCT07206355
Recruiting
Phase 3

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

Biliary Tract Cancer (BTC)Advanced Biliary Tract Cancer
J-Pharma Co., Ltd.480 enrolled18 locationsNCT07265674
Recruiting
Not Applicable

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Biliary Tract Cancer (BTC)
Peking University40 enrolled2 locationsNCT07466238
Recruiting
Phase 1

Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors

Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+5 more
I-Mab Biopharma US Limited330 enrolled21 locationsNCT04900818
Recruiting
Phase 1

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Advanced Solid TumorsEwing SarcomaHepatocellular Carcinoma (HCC)+1 more
SEED Therapeutics, Inc.171 enrolled6 locationsNCT07197554
Recruiting
Phase 1Phase 2

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

Pancreatic Ductal AdenocarcinomaBiliary Tract Cancer (BTC)Gastric or Gastroesophageal Junction Adenocarcinoma
Phanes Therapeutics258 enrolled11 locationsNCT05482893
Recruiting
Phase 2

Paclitaxel mIcelle Later-line cOmbined immunoTherapy for Biliary Tract Cancer

Biliary Tract Cancer (BTC)
Peking Union Medical College Hospital100 enrolled1 locationNCT07159204